231 related articles for article (PubMed ID: 24531781)
1. Risk adapted chemoprevention for prostate cancer: an option?
Schmitz-Dräger BJ; Schöffski O; Marberger M; Sahin S; Schmid HP
Recent Results Cancer Res; 2014; 202():79-91. PubMed ID: 24531781
[TBL] [Abstract][Full Text] [Related]
2. [Chemoprevention of prostate cancer - a plea].
Schmitz-Dräger BJ; Bismarck E; Schöffski O; Fischer C
Aktuelle Urol; 2012 May; 43(3):157-61. PubMed ID: 22639024
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of prostate cancer.
Vemana G; Hamilton RJ; Andriole GL; Freedland SJ
Annu Rev Med; 2014; 65():111-23. PubMed ID: 24188663
[TBL] [Abstract][Full Text] [Related]
4. Prevention strategies for prostate cancer.
Schmitz-Dräger BJ; Lümmen G; Bismarck E; Fischer C
Minerva Urol Nefrol; 2012 Dec; 64(4):225-31. PubMed ID: 23288209
[TBL] [Abstract][Full Text] [Related]
5. [Chemoprevention of prostate cancer. Current status].
Schmitz-Dräger BJ; Lümmen G; Schäfer RM
Urologe A; 2007 Jun; 46(6):611-5. PubMed ID: 17483928
[TBL] [Abstract][Full Text] [Related]
6. [Pharmaco and diet based prostate cancer prevention].
Eisinger F; Cancel-Tassin G; Azzouzi AR; Gravis G; Rossi D; Cussenot O
Bull Cancer; 2013 May; 100(5):497-507. PubMed ID: 23694994
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer chemoprevention with 5α-reductase inhibitors.
Nepple KG; Andriole GL
Urol Oncol; 2012 Sep; 30(5):553-4. PubMed ID: 23193568
[No Abstract] [Full Text] [Related]
8. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
9. [Letter to P. Hammerer. chemoprevention of prostate cancer. Act Urol. 2012; 43].
Schmitz-Dräger BJ
Aktuelle Urol; 2013 Jan; 44(1):53. PubMed ID: 23381879
[No Abstract] [Full Text] [Related]
10. An update on chemoprevention strategies in prostate cancer for 2006.
Neill MG; Fleshner NE
Curr Opin Urol; 2006 May; 16(3):132-7. PubMed ID: 16679848
[TBL] [Abstract][Full Text] [Related]
11. [Role of 5 alpha-reductase inhibitors in the chemoprevention of prostate cancer].
An C; Xu T; Wang XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):582-6. PubMed ID: 22338147
[TBL] [Abstract][Full Text] [Related]
12. Phase III prostate cancer chemoprevention trials.
Parnes HL; Brawley OW; Minasian LM; Ford LG
Recent Results Cancer Res; 2014; 202():73-7. PubMed ID: 24531780
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of colorectal cancer.
Das D; Arber N; Jankowski JA
Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS; Fleshner NE; Thompson IM
Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of prostate cancer: what can be recommended to patients?
Colli JL; Amling CL
Curr Urol Rep; 2009 May; 10(3):165-71. PubMed ID: 19371472
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of prostate cancer.
Klein EA
Annu Rev Med; 2006; 57():49-63. PubMed ID: 16409136
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of prostate cancer: agents and study designs.
Thompson IM
J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117
[TBL] [Abstract][Full Text] [Related]
18. Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?
Hoffman RM; Roberts RG; Barry MJ
J Gen Intern Med; 2011 Jul; 26(7):798-801. PubMed ID: 21222171
[TBL] [Abstract][Full Text] [Related]
19. 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
Hamilton RJ; Freedland SJ
BMC Med; 2011 Sep; 9():105. PubMed ID: 21920036
[TBL] [Abstract][Full Text] [Related]
20. Finasteride.
Chaudhary UB; Turner JS
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):873-81. PubMed ID: 20536414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
